Last updated 2026-08-09
- Raised $400M PIPE led by Blackstone, Feb 2026
- Raised $150M PIPE led by Abingworth, Mar 2024
- Raised $358M PIPE led by Fidelity Ventures, Jan 2018
Total raised
$908.0M
Last: PIPE 2026-03
Stage
Public
Founded
1901
Headcount
500+
HQ
Tel Aviv, Israel
Sector
Health Tech & Life Sciences
About
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company that specializes primarily in generic drugs, but also has interests in branded drugs, active pharmaceutical ingredients (APIs), contract manufacturing services, and an out-licensing platform. Founded in 1901, Teva has grown to be a world leader in generic and specialty medicines, with a portfolio of over 3,600 medicines. The company is committed to increasing access to high-quality healthcare globally by developing, producing, and marketing affordable generic drugs and innovative pharmaceuticals.
Funding history · 5 rounds · $908.0M total
2026-02
PIPE
$400.0M
★ Blackstone
2024-03
PIPE
$150.0M
★ Abingworth
2018-01
PIPE
$358.0M
★ Fidelity Ventures★ Berkshire Hathaway
1981-12
Follow-on PO
Undisclosed
1950-12
Follow-on PO
Undisclosed
Q&A
- What was Teva Pharmaceuticals' most recent funding round?
- In March 2026, Teva Pharmaceuticals completed a PIPE funding round, raising $400,000,000 from Blackstone Life Sciences.
- When was Teva Pharmaceuticals founded and what is its primary focus?
- Teva Pharmaceutical Industries Ltd. was founded in May 1901. It is a global pharmaceutical company specializing in the development, production, and marketing of generic drugs, specialty pharmaceuticals, and active pharmaceutical ingredients.
- What is the employee count for Teva Pharmaceuticals?
- Teva Pharmaceuticals has 500+ employees.
- What was the amount and date of Teva Pharmaceuticals' most recent debt financing?
- In January 2024, Teva Pharmaceuticals secured $2,445,000,000 in Debt Financing.
- Which company did Teva Pharmaceuticals acquire in April 2026?
- In April 2026, Teva Pharmaceuticals acquired Emalex Biosciences for $900,000,000.
- What was one of Teva Pharmaceuticals' significant public offerings in recent years?
- In February 2023, Teva Pharmaceuticals completed a Public Offering, raising $2,060,000,000.
- Who are some of the current executive leaders at Teva Pharmaceuticals?
- Richard Francis serves as President and Chief Executive Officer, and Eli Kalif is the Executive Vice President, Chief Financial Officer (CFO) at Teva Pharmaceuticals.
- What was the amount of the Public Offering Teva Pharmaceuticals completed in May 2025?
- In May 2025, Teva Pharmaceuticals completed a Public Offering, raising $2,189,000,000.
Team · 26
Chaim Salomon
Founder · Founder
Moshe Levin
Founder · Founder
Yitschak Elstein
Founder · Founder
Günther Friedländer
Founder · Founder
Eli Kalif
Executive Vice President, Chief Financial Officer (CFO)
Christine Fox
Executive Vice President, US Commercial, Head of Innovative Franchise
Dr. Eric A. Hughes
Executive Vice President, Global R&D and Chief Medical Officer
Placid Jover
Executive Vice President, Chief Human Resources Officer
Evan Lippman
Executive Vice President, Business Development
David McAvoy
Executive Vice President, Chief Legal Officer
Matthew Shields
Executive Vice President, Teva Global Operations
Nir Baron
Senior Vice President, Chief Internal Auditor
Kathleen Veit
Senior Vice President, Global Compliance & Ethics Officer
Dr. Sol J. Barer
Chairman of the Board of Directors
Rosemary A. Crane
Independent Director
Amir Elstein
Independent Director
Chen Lichtenstein
Independent Director
Gerald M. Lieberman
Independent Director
Roberto A. Mignone
Independent Director
Dr. Perry D. Nisen
Independent Director
Prof. Ronit Satchi-Fainaro
Independent Director
Dr. Tal Zaks
Independent Director
Prof. Varda Shalev
Director
Sectors & technology
Primary sector
Health Tech & Life Sciences
Technologies
Target customers
Business model
B2CB2B
Highlights
Patents
Tags
respiratorywomen-healthneurologyoncologygeneric-drugsbiological-therapypharmaceuticalspatientsbiopharmaceuticalnanotechnologychronic-patientsdrug-deliverydoctorsmedical-cannabis
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | tevapharm.com |
|---|---|
| linkedin.com/company/5239 | |
| X / Twitter | twitter.com/tevapharm |
| facebook.com/tevapharm | |
| YouTube | youtube.com/channel/UC9mY1-jUvXsEIS5A2_EjpFg |
| Wikipedia | en.wikipedia.org/wiki/Teva_Pharmaceuticals |
| Wikidata | wikidata.org/wiki/Q898750 |
Identifiers & details
| Legal name | Teva Pharmaceutical Industries Ltd. |
|---|---|
| Founded | 1901-5 |
| Employees (exact) | 36830 |
| Wikidata QID | Q898750 |
Acquisitions & public offerings
| Acquired | Date | Amount |
|---|---|---|
| Emalex Biosciences | 2026-04 | $900.0M |
| Anda | 2016-10 | $500.0M |
| Actavis Generics | 2016-08 | $40.0B |
| Rimsa | 2015-10 | $2.3B |
| Gecko Health Innovations | 2015-09 | |
| Auspex Pharmaceuticals | 2015-03 | $3.5B |
| Labrys Biologics | 2014-06 | $825.0M |
| NuPathe | 2014-01 | $144.0M |
| MicroDose Therapeutx | 2013-06 | $165.0M |
| Taiyo Pharmaceutical Industry | 2011-07 | $934.0M |
| Cephalon | 2011-05 | $6.8B |
| Ratiopharm | 2010-01 | |
| Barr Pharmaceuticals | 2008-12 | $7.5B |
| Bentley Pharmaceuticals (generic operations) | 2008-07 | $360.0M |
| Ivax Corporation | 2006-01 | $7.4B |
| Sicor, Inc. | 2004-01 | |
| Novopharm | 2000-01 | |
| Copley Pharmaceutical | 1999-08 | $220.0M |
| Biocraft | 1996-01 | |
| Biogal Gyógyszergyár Rt. | 1995-01 | |
| ICI (Italy) | 1995-01 | |
| Lemmon Pharmacal Company | 1985-01 | |
| Ikapharm | 1980-01 | |
| Plantex | 1980-01 | |
| Assia and Zori | 1976-01 | |
| Orphahell |
Radar intelligence
Patents
| EPO | 1106 |
|---|
App Store
| App | Rating | Ratings |
|---|---|---|
| Teva Pharmaceutical Events | ||
| Teva Meetings |
Web history (Wayback)
| Domain | tevapharm.com |
|---|
Wikidata
| QID | Q898750 |
|---|